Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Large Decline in Short Interest

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 5,240,000 shares, a drop of 30.4% from the September 15th total of 7,530,000 shares. Based on an average daily volume of 2,450,000 shares, the days-to-cover ratio is currently 2.1 days.

Insider Buying and Selling

In related news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the firm's stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the acquisition, the insider now directly owns 7,090,351 shares in the company, valued at $38,004,281.36. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 12.00% of the company's stock.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors have recently made changes to their positions in CAPR. Vanguard Group Inc. raised its holdings in shares of Capricor Therapeutics by 17.2% in the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock worth $9,274,000 after acquiring an additional 200,499 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics in the second quarter worth $426,000. Renaissance Technologies LLC raised its holdings in shares of Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock worth $656,000 after acquiring an additional 84,350 shares during the last quarter. Rhumbline Advisers acquired a new position in Capricor Therapeutics in the second quarter valued at $147,000. Finally, Bank of New York Mellon Corp increased its stake in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock valued at $381,000 after purchasing an additional 9,040 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CAPR has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $8.00 price target on shares of Capricor Therapeutics in a research note on Friday, September 20th. Oppenheimer reaffirmed an "outperform" rating and issued a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Capricor Therapeutics in a research note on Wednesday. Finally, Maxim Group raised their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research note on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $22.60.

Capricor Therapeutics Stock Up 3.7 %

Shares of Capricor Therapeutics stock traded up $0.63 during trading on Friday, hitting $17.77. 4,593,738 shares of the company were exchanged, compared to its average volume of 1,081,583. Capricor Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $21.98. The firm has a 50 day moving average price of $7.44 and a 200 day moving average price of $6.07. The stock has a market capitalization of $568.27 million, a price-to-earnings ratio of -20.43 and a beta of 4.01.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The company had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. Analysts predict that Capricor Therapeutics will post -1.13 earnings per share for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.